Mesirow Financial Investment Management Inc. increased its stake in Cara Therapeutics Inc (NASDAQ:CARA) by 12.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,432 shares of the biopharmaceutical company’s stock after purchasing an additional 3,611 shares during the period. Cara Therapeutics accounts for about 2.6% of Mesirow Financial Investment Management Inc.’s portfolio, making the stock its 3rd largest position. Mesirow Financial Investment Management Inc. owned about 0.08% of Cara Therapeutics worth $719,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in CARA. Deutsche Bank AG increased its holdings in Cara Therapeutics by 141.9% in the 4th quarter. Deutsche Bank AG now owns 304,177 shares of the biopharmaceutical company’s stock worth $3,953,000 after acquiring an additional 178,414 shares in the last quarter. First Manhattan Co. grew its holdings in shares of Cara Therapeutics by 17.3% during the first quarter. First Manhattan Co. now owns 981,220 shares of the biopharmaceutical company’s stock worth $19,251,000 after buying an additional 144,578 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Cara Therapeutics during the fourth quarter worth $1,578,000. BlackRock Inc. grew its holdings in shares of Cara Therapeutics by 1.5% during the fourth quarter. BlackRock Inc. now owns 2,800,605 shares of the biopharmaceutical company’s stock worth $36,407,000 after buying an additional 42,487 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Cara Therapeutics by 109.5% in the fourth quarter. Two Sigma Advisers LP now owns 39,600 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 20,700 shares during the period. Institutional investors and hedge funds own 58.03% of the company’s stock.
In related news, CEO Derek T. Chalmers sold 5,528 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $21.42, for a total transaction of $118,409.76. Following the transaction, the chief executive officer now directly owns 963,996 shares of the company’s stock, valued at approximately $20,648,794.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frederique Ph.D. Menzaghi sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $23.24, for a total value of $464,800.00. Following the completion of the sale, the senior vice president now owns 99,886 shares of the company’s stock, valued at $2,321,350.64. The disclosure for this sale can be found here. Insiders have sold a total of 120,848 shares of company stock valued at $2,844,442 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.Shares of NASDAQ CARA opened at $23.99 on Friday. Cara Therapeutics Inc has a 1-year low of $12.19 and a 1-year high of $27.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.11 and a quick ratio of 3.11. The stock has a fifty day moving average price of $23.59 and a 200 day moving average price of $19.96. The company has a market cap of $953.65 million, a PE ratio of -11.65 and a beta of 2.18.
Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.03. The company had revenue of $5.21 million during the quarter, compared to the consensus estimate of $5.14 million. Cara Therapeutics had a negative return on equity of 68.36% and a negative net margin of 420.97%. Analysts anticipate that Cara Therapeutics Inc will post -2.32 earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on the stock. Piper Jaffray Companies upped their price objective on shares of Cara Therapeutics from $35.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 12th. Laidlaw upped their price objective on shares of Cara Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, May 29th. Needham & Company LLC upped their target price on shares of Cara Therapeutics from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, May 29th. Finally, BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Cara Therapeutics has an average rating of “Buy” and an average price target of $26.94.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.
See Also: What is Compound Interest?
Receive News & Ratings for Cara Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cara Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.